Drug intelligence / Profile preview

B-Pink

Development stage: Unknown
Lead developer: Elliott Labs
Modality: Small Molecules
Administration: Oral

Overview

B-Pink is an oral nutritional supplement developed and marketed by Elliott Labs in India. It is a combination product containing ferrous ascorbate, folic acid, cyanocobalamin (vitamin B12), and cholecalciferol (vitamin D3). It is primarily indicated for the treatment of nutritional deficiencies, including iron deficiency anemia. Ferrous ascorbate serves as a source of iron to restore hemoglobin levels and support oxygen transport. Folic acid and cyanocobalamin are essential for red blood cell formation and DNA synthesis, while cholecalciferol supports calcium homeostasis and bone mineralization. The product is available as a tablet formulation and is approved for marketing in India.

Brand names: B-Pink

Targets

MTR (Methionine synthase)VDR (Vitamin D receptor)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on B-Pink.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-Pink.

Explore the full profile